Synapse - Raajit Rampal

Results (338)

Clinical Factors but not somatic mutations predict for survival in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplant: Analysis of the North American myelofibrosis transplant outcome (NAMTO) study

Meeting Abstract

Ajufo, H.; Derkach, A.; Rampal, R. K.; Famulare, C.; Nemirovsky, D.; Chervin, J.; Ho, V.; Gupta, V.; Viswabandya, A.; Deeg, H. J.; more...
Blood (2023)

Fulltext@MSK | Save

Clinical practice gaps in managing patients with myelofibrosis: Comparison of healthcare professional and expert treatment choices provided to an online decision support tool

Meeting Abstract

Topping, R. P.; Bose, P.; Mascarenhas, J.; Rampal, R. K.; Stein, B. L.; Quill, T. A.; Mesa, R. A.
Blood (2023)

Fulltext@MSK | Save

A phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in patients with JAK inhibitor-naive myelofibrosis and moderate thrombocytopenia (XPORT-MF-044)

Meeting Abstract

Scandura, J. M.; Gerds, A. T.; Ritchie, E. K.; Wang, X.; Kye, S.; Rampal, R. K.
Blood (2023)

Fulltext@MSK | Save

A phase 1b trial of DISC-0974, an anti-hemojuvelin antibody, in patients with myelofibrosis and anemia

Meeting Abstract

Gangat, N.; Foran, J. M.; Halpern, A. B.; Rampal, R. K.; Novikov, N.; Buch, A.; Pelletier, O.; Savage, W.; Tefferi, A.
Blood (2023)

Fulltext@MSK | Save

Impact of symptom benefit and transfusion response on survival in myelofibrosis patients treated with pacritinib: PERSIST-2 landmark survival analysis

Meeting Abstract

Ajufo, H.; Bewersdorf, J. P.; Harrison, C. N.; Palandri, F.; Mascarenhas, J.; Palmer, J.; Gerds, A. T.; Kiladjian, J. J.; Buckley, S.; Derkach, A.; more...
Blood (2023)

Fulltext@MSK | Save

A phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

Meeting Abstract

Bewersdorf, J. P.; Derkach, A.; Masarova, L.; Pemmaraju, N.; Stein, E. M.; Mauro, M.; Rampal, R. K.; Bose, P.
Blood (2023)

Fulltext@MSK | Save

Long-term outcomes with single-agent BRAF-inhibitor therapy in Erdheim-Chester disease

Meeting Abstract

Goyal, G.; Reiner, A.; Bossert, D.; Sigler, A.; Buthorn, J.; Lacouture, M.; Rotemberg, V.; Francis, J. H.; Go, R. S.; Rampal, R. K.; more...
Blood (2023)

Fulltext@MSK | Save

Pelabresib in combination with ruxolitinib for Janus Kinase inhibitor treatment-naïve patients with myelofibrosis: Results of the MANIFEST-2 randomized, double-blind, phase 3 study

Meeting Abstract

Rampal, R. K.; Grosicki, S.; Chraniuk, D.; Abruzzese, E.; Bose, P.; Gerds, A. T.; Vannucchi, A. M.; Palandri, F.; Lee, S. E.; Gupta, V.; more...
Blood (2023)

Fulltext@MSK | Save

Phase 1/2 study of TP-3654, a selective PIM1 kinase inhibitor: Preliminary data showed clinical activity and cytokine reductions in relapsed/refractory myelofibrosis patients